Reg CF · Preferred Stock · Apr 2026

OpenReached targetReg CFPreferred Equity

via WeFunder · last checked Oct 8, 2026View campaign

Raised

$3.1M / $3.2M max

96% of ceiling · target hit day 113

Investors

1,215

$2.5K avg

Momentum

$19K/day

best $103K · 203 days left

Raised over time

Cumulative raisedInvestors

$3.1M$1.5M$0

1.2K6080

Apr 28, 2026 · openedOct 8, 2026 · latest

Target ($50K) hit — Aug 19, 2026, day 113$1.0M raised — Aug 19, 2026Deadline Apr 30, 2027 — 204 days out

Left axis: cumulative dollars raised. Right axis: cumulative investors. Live figures via WeFunder, last checked Oct 8, 2026; investor counts may lag the platform by up to a day.

Financials disclosed in this offering

FY2024–FY2025 · hover for source

−$2.9M

FY2024

$2.5M

−$1.8M

FY2025

RevenueNet income

Metric

FY2024 reviewed

FY2025 reviewed

Income statement

Revenue

$2,535,657

Cost of goods sold

$218,824

$2,257,925

Gross margin

—

11%

Net income

-$2,930,382

-$1,837,486

Taxes paid

Balance sheet

Cash

$70,701

$2,954

Accounts receivable

$335,348

$288,547

Total assets

$2,134,379

$1,988,496

Short-term debt

$8,094,966

$8,985,924

Long-term debt

$5,383,366

$4,487,734

Total liabilities

$13,478,332

$13,473,658

Other

Headcount

—

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

2 amendments

Aug 11, 2026
- Maximum $1.2M → $3.2M
“Adding audited financials and increasing maximum”
Form C/A on EDGAR ↗
Jun 18, 2026
- Maximum $500K → $1.2M
“Increasing maximum target”
Form C/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. The quoted reason is the issuer’s own statement from the Form C/A.

Deal terms

Pre-money$59.4M

Price / share$0.91

Shares offered60,241

Post-money is computed as pre-money + amount raised, so it moves while the round is open — it’s shown once the round closes.

Perks

Digital Science Library: Access to repository of relevant papers, FDA guidance documents, and veterinary cardiology resources$1K+

Bi-annual Strategy Calls: Direct conversations with leadership on progress, milestones, and roadmap$5K+

AMA Founder Office Hours: Founder-led office hours focused on company progress and longer-term strategy$10K+

Annual 1-on-1 Zoom call with Rejuvenate Bio's founders. Priority consideration for a dog of choice for beta access if clinical & regulatory eligibility criteria are met at launch ($25K+

Attempts to include pictures of a dog of choice on therapeutic packaging (subject to regulatory, partner, & manufacturing constraints; not guaranteed)$50K+

Only available to the first advocate to invest at this level. Attempts to include your dog's name in drug naming (subject to regulatory, partner, & manufacturing constraints; not g$500K+

Offering details

Target$50,000

Max$3,200,000

Min investment—

OpenedApr 28, 2026

DeadlineApr 30, 2027

Days active164

Days to deadline203

Links & provenance

Campaign page Pitch video SEC filing

Source: SEC EDGAR
0001859067-26-000003
Last synced Oct 8, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.